⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL303947 | 0.74 | — | — | |
| SCHEMBL4321838 | 0.72 | — | — | |
| SCHEMBL28277149 | 0.72 | — | — | |
| SCHEMBL27639860 | 0.71 | THRB (0.47) | — | |
| SCHEMBL3791906 | 0.70 | — | — | |
| SCHEMBL4281970 | 0.70 | ALOX15 (0.46) | — | |
| SCHEMBL17469360 | 0.69 | — | — | |
| SCHEMBL28292971 | 0.69 | — | — | |
| SCHEMBL2492419 | 0.67 | — | — | |
| SCHEMBL9485098 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1027 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024137663-A2 | TREATMENT OF DKK2 RELATED DISEASES AND DISORDERS | EMPIRICO INC. (US) | 2024-06-27 | — | — | WO | claimed |
| WO-2024129886-A2 | TREATMENT OF MST1 RELATED DISEASES AND DISORDERS | EMPIRICO INC. (US) | 2024-06-20 | — | — | WO | claimed |
| WO-2024121576-A1 | AFFINITY PROBES | Qbiotix Limited (GB) | 2024-06-13 | — | — | WO | claimed |
| WO-2024118979-A1 | TREATMENT OF MTRES1 RELATED DISEASES AND DISORDERS | EMPIRICO INC. (US) | 2024-06-06 | — | — | WO | claimed |
| EP-4367125-A1 | AMINOOXY CLICK CHEMISTRY (AOCC): A VERSATILE BIOCONJUGATION APPROACH | Alnylam Pharmaceuticals, Inc. (US) | 2024-05-15 | — | — | EP | claimed |
| EP-4355355-A1 | TREATMENT OF PLIN1 RELATED DISEASES AND DISORDERS | EMPIRICO INC. (US) | 2024-04-24 | — | — | EP | claimed |
| EP-4355878-A1 | TREATMENT OF MTRES1 RELATED DISEASES AND DISORDERS | EMPIRICO INC. (US) | 2024-04-24 | — | — | EP | claimed |
| WO-2024073732-A1 | MODIFIED DOUBLE-STRANDED RNA AGENTS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-04-04 | — | — | WO | claimed |
| WO-2023283434-A9 | AMINOOXY CLICK CHEMISTRY (AOCC): A VERSATILE BIOCONJUGATION APPROACH | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-03-28 | — | — | WO | claimed |
| WO-2024006999-A2 | CYCLIC-DISULFIDE MODIFIED PHOSPHATE BASED OLIGONUCLEOTIDE PRODRUGS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-01-04 | — | — | WO | claimed |
| WO-2007021896-A2 | CHEMICALLY MODIFIED OLIGONUCLEOTIDES FOR USE IN MODULATING MICRO RNA AND USES THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2007-02-22 | — | — | WO | claimed |
| EP-1735009-A2 | iRNA AGENTS TARGETING VEGF | Alnylam Pharmaceuticals Inc. (US) | 2006-12-27 | — | — | EP | claimed |
| WO-2006073602-A9 | RNAI MODULATION OF THE BCR-ABL FUSION GENE AND USES THEREOF | ALNYLAM PHARMACEUTICALS INC (US) | 2006-09-28 | — | — | WO | claimed |
| WO-2006073602-A2 | RNAI MODULATION OF THE BCR-ABL FUSION GENE AND USES THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2006-07-13 | — | — | WO | claimed |
| US-6967199-B2 | Substituted diamine derivatives useful as motilin antagonists | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2005-11-22 | — | — | US | claimed |
| WO-2005089224-A2 | iRNA AGENTS TARGETING VEGF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2005-09-29 | — | — | WO | claimed |
| US-20030203906-A1 | A phenylamide derivatives for treating gastrointestinal reflux disorders, eating disorder obesity and irritable bowel disorder | JOHNSON SIGMONG G (US) | 2003-10-30 | — | — | US | claimed |
| EP-1294695-A2 | SUBSTITUTED DIAMIDE DERIVATIVES USEFUL AS MOTILIN ANTAGONISTS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2003-03-26 | — | — | EP | claimed |
| US-20020013352-A1 | For therapy of gastrointestinal reflux disorders, eating disorders leading to obesity and irritable bowel disorder | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-01-31 | — | — | US | claimed |
| WO-2001085694-A2 | SUBSTITUTED DIAMIDE DERIVATIVES USEFUL AS MOTILIN ANTAGONISTS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2001-11-15 | — | — | WO | claimed |